News

BioXcel IGALMI shows efficacy in at-home agitation trial data across all severity levels, with largest effect in severe episodes...

Zenas BioPharma files BLA for obexelimab in IgG4-Related Disease following Phase 3 results showing 56% reduction in flare risk.

Pfizer partners with Innovent Biologics on 12 oncology programs in $10.5B deal, focusing on ADCs and multispecific antibodies.

Blackstone commits $1.3B to Apogee's zumilokibart in largest pre-Phase 3 royalty deal, providing non-dilutive financing through commercialization.

Bonito Biosciences and DaltonTx partner to advance CNS oligotherapeutic delivery using AI-driven screening and computational design for blood-brain barrier...

Lilly acquires shingles vaccine candidate amezosvatein for up to $1.5B, targeting tolerability improvements over existing options.

Blackstone Life Sciences provides $1.3B in royalty financing and debt for Apogee's zumilokibart, signaling confidence in the IL-13 inhibitor's...

GENFIT advances ACLF definition alignment efforts at EASL 2026 while collecting elafibranor royalties from Ipsen's Iqirvo franchise.

Scilex spins out Semnur Pharmaceuticals via stock dividend, creating an OTC-traded entity for its Phase 3 SEMDEXA candidate.

CordenPharma acquires AmbioPharm to expand peptide manufacturing across three continents, adding critical purification and lyophilization capacity.